Introduction {#sec1-1}
============

Cancer is a multicellular disease that can arise from any cell types and organs with a multi-factorial etiology (Hanahan and Weinberg 2000). It is the leading cause of death worldwide, accounting for 7.6 million deaths (around 13% of all deaths) in 2008 according to World health organization (WHO). In Cancer patients, chemotherapy is the only choice of treatment. Unfortunately, development of drug resistance in tumor after treatment is always a major obstacle to the successful management of cancer (Wu et al., 2006). Thus, developing new therapeutic agents that can overcome drug resistance becomes an urgent need for cancer patients.

Steroids have always attracted considerable attention because of being a fundamental class of biological signaling molecules. They can regulate a variety of biological processes, so they are considered good candidates for drug development in treatment of large number of diseases including cardiovascular (Dubey et al., 2002), autoimmune diseases (Latham et al., 2003), brain tumors, breast cancer, prostate cancer, osteoarthritis, etc. (Sheridan et al., 1988). Presence of different functional groups located around the rigid tetracyclic core leads to diversity in the biological actions as these serve as substrates for different targets. In recent time a lot of attentions have been paid on structural modification of steroid compounds through incorporation of heteroatoms (Elmegeed et al., 2011; Zhang et al., 2013). These hetero atoms may be present in the main ring system or in the additional fused ring. The incorporation of different types of heteroatoms to steroid skeleton enhanced their various biological activities (Singh et al., 1991).

Multicomponent reactions (MCRs) are considered a superior method for the productionof small-molecule compoundslibraries and are indispensable for structure-activity relationship (SAR) studies. In a typical multicomponent process, more than two components are combined in a one reaction, thereby enrolling an operationally effective and highly modular wayof the synthesis of structurally diverse molecular entities (Váradiet al., 2016). Recently several modified steroids were synthesized via MCRs (Mohareb et al., 2016).

Nanoparticales (NP) have been considered potent drug vehicles due to their numerous important technological advantages, for instance, long half-life, high loading capacity (Ghosh et al., 2010). Also, NP are well known to concentrate mostly at cancer sites due to poor lymphatic drainage of macro-molecules in these sites and the enhanced permeability and retention effect (EPR) of cancer cells due to which the NP can pass through enlarged pores in the capillary endothelium pores of tumor cells (Lammers et al., 2008). Nanoparticales surface can be modified by using highly hydrophilic polymers, such as polyethyleneglycol (PEG) which are hydrophobic surfaces. The addition of PEG to the NP formulation increases the retention and circulation time by reducing uptake by opsonins in the Reticuloendothelialsystem (RES). It was reported previously that particles remained in rat circulation 40-times longer when coated than uncoated with PEG (Tan et al., 1993).

Our research group have many trials to develop facile and convenient route for the synthesis of steroid based compounds containing heteroatoms and screening their biological activities (Elmegeed et al., 2005; El-Far et al., 2009; Elmegeed et al., 2015). Encouraged by the preceding information, the goal of these investigations is to develop new drug candidates for cancer treatment. Steroidal heterocycles have been prepared via MCRs and converted to NP and tested in-vitro against liver, breast and colon cancer human cell lines.

Materials and Methods {#sec1-2}
=====================

Synthetic methods, analytical and spectral data {#sec2-1}
-----------------------------------------------

Starting steroid 5α-cholestan-3-one, was purchased from Sigma Company, St. Louis, MO, USA. All solvents were anhydrated by distillation before its use. All melting points were measured using an Electrothermal apparatus and are uncorrected. The IR spectra were recorded in (KBr discs) on a shimadzu FT-IR 8201 PC spectrometer and expressed in cm^-1^. The ^1^HNMR and ^13^CNMR spectra were recorded with Jeol instrument (Japan), at 270 and 125 MHz respectively, in DMSO-d~6~ as solvent and chemical shifts were recorded in ppm relative to TMS. The spin multiplicities were abbreviated by the letters: s-singlet, d-doublet, t-triplet, q-quartet and m (multiplet, more than quartet). Mass spectra were recorded on a GCMS-QP 1000 ex spectra mass spectrometer operating at 70 eV. Elemental analyses were carried by the Microanalytical Data Unit at the National Research Centre, Giza, Egypt and the Microanalytical Data Unit at Cairo University, Giza, Egypt. The reactions were monitored by thin layer chromatography (TLC) which was carried out using Merck 60 F254 aluminum sheets and visualized by UV light (254 nm). The mixtures were separated by preparative TLC and gravity chromatography. All steroid derivatives showed the characteristic spectral data of cyclopentanoperhydrophenanthrene nuclei of cholestane series were similar to those reported in literature (Gacs-Baitz et al., 1990).

General procedure for compounds 1 and 2 {#sec2-2}
---------------------------------------

A mixture of 5α-cholestan-3-one (0.38 g, 1mmol), p-methoxybenzaldahyde (0.13 g, 1mmol) and malononitrile (0.06 g, 1mmol) in absolute ethanol (50 ml) containing ammonium acetate (0.98 g, 2% excess) or piperidine (1ml) was heated under reflux for 4-5 hours until all starting materials had disappeared as indicated by TLC. The reaction mixture was treated with ice/water mixture. The formed solid product, in each case, was collected by filtration and crystallized from absolute ethanol.

8-Amino-10-(4-methoxyphenyl)-11a, 13a-dimethyl-1-octyl2, 3, 3a, 3b, 4, 5, 5a, 6, 6a, 7, 11, 11a, 11b, 12, 13, -13a-hexadecahydro-1H-cyclopenta\[5,6\]naphtho\[1,2-g\]quinoline-9-carbonitrile (1).

Yellow crystals, yield 0.48 g (85%); mp 105 -107 °C; IR (KBr, cm^-1^): υ 3435-3350 (NH~2~-NH), 2936, 2864 (CH-aliphatic), 1032 (CH-aromatic), 2211 (CN), 1566 (C=C). ^1^HNMR (DMSO-d~6~, ppm): δ= 0.84 (s, 3H, CH~3~-19), 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 0.95 (s, 3H, CH~3~), 1.09 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.73 (s, 3H, OCH~3~), 6.86 (s, 2H, NH~2~, D~2~O-exchangeable), 6.96 -- 7.42 (m, 4H- aromatic-H). ^13^CNMR (DMSO-d~6~-ppm): δ= 28.30 (C-1), 50.10 (C-3), 38.90 (C-4), 40.10 (C-5), 27.20 (C-6), 27.90 (C-7), 35.70 (C-8), 35.00 (C-9), 46.50 (C-10), 22.70 (C-11), 35.72 (C-12), 46.40 (C-13), 46.20 (C-14), 27.30 (C-15), 29.80 (C-16), 47.90 (C-17), 20.40 (C-18), 21.10 (C-19),115.90 (CN), 131.60, 139.90 (C=C), 19.4, 23.2, 23.2 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 56.10 (C-OCH~3~),113.90, 128.20, 127.40, 159.20, 143.50 (C-aromatic). MS (EI): m/z (%):570 (M^+^+1, 60), 462 (8), 344 (8), 225 (9), 81 (40), 64 (80). Calc for C~38~H~55~N~3~O (569.863): C,79.95; H, 9.61; N, 7.56, found: C, 80.06; H, 9.53; N, 7.25 %.

8-Amino-10-(4-methoxyphenyl)-11a,13a-dimethyl-1-octyl-1, 2, 3, 3a, 3b, 4, 5, 5a, 6, 6a, 11, 11a, 11b, 12, 13, -13a-hexadecahydrocyclopenta\[5,6\]naphtho\[1,2g\]-chromene-9-carbonitrile (2).

Dark orange crystals, yield 0.43 g (76%); mp 77-80 °C; IR (KBr, cm^-1^): υ 3452-3350 (NH~2~-NH), (NH~2~), 2934, 2865 (CH-aliphatic), 2217 (CN), 1604 (C=C). ^1^HNMR (DMSO-d~6~, ppm): δ =0.82 (s, 3H, CH~3~-19), 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 1.18 (s, 3H, CH~3~-18), 1.25- 1.33 (m-6H, 3CH~2~-aliphatic), 3.74 (s, 3H, OCH~3~), 4.20 (S, 1H, pyrane), 6.34 (s, 2H, NH~2~, D~2~O-exchangeable), 6.84--7.11 (m, 4H- aromatic-H). ^13^CNMR (DMSO, ppm): δ= 27.20 (C-1), 53.80 (C-3), 35.90 (C-4), 40.10 (C-5), 27.20 (C-6), 27.90 (C-7), 35.70 (C-8), 35.00 (C-9), 46.50 (C-10), 22.70 (C-11), 35.72 (C-12), 46.40 (C-13), 46.20 (C-14), 27.30 (C-15), 29.80 (C-16), 47.90 (C-17), 20.40 (C-18), 21.10 (C-19), 115.90 (CN), 131.6, 139.9 (C=C), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic),56.10 (C-OCH~3~), 114.20, 127.40, 159.90 (C-aromatic). MS (EI): m/z (%): 570 (M^+^, 66), 517 (40), 80 (35), 64 (100). Calc for C~38~H~54~N~2~O~2~ (570.848): C, 79.81; H, 9.41; N, 5.03, found: C, 79.72; H, 9.39; N, 5.10 %.

Synthetic procedure for compounds 3 {#sec2-3}
-----------------------------------

12-(4-Methoxyphenyl)-13a,15a-dimethyl-1-octyl-10-phenyl-1, 2, 3, 3a, 3b, 4, 5, 5a, 6, 6a, 7, 10, 13, 13a, -13b, 14, 15, 15a-octadecahydro-11H-cyclopenta\[5,6\]naphtho\[1,2-g\]pyrimido\[4,5-b\]quinolin-11-imine (3).

To a 1mmol from compound 1 (0.57 g) in absolute ethanol (30 ml), 1 ml glacial acetic acid was added, and equimolar amount of aniline (0.09 g, 1 mmol). The reaction mixture was heated under reflux about 2-3 hr until all starting materials had disappeared as indicated by TLC. The reaction mixture was neutralized with sodium bicarbonate, the formed solid product was collected by filtration, dried and crystallized from ethanol (95%).

Pale yellow crystals, yield 0.60 g (90%); mp 100-103 °C; IR (KBr, cm^-1^): υ 3293 (NH), 2926, 2857 (CH-aliphatic), 1600 (C=C). ^1^HNMR (DMSO-d~6~, ppm): δ= 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.87 (s, 3H, CH~3~-19), 0.93 (d, 3H, 21-CH~3~), 1.25- 1.33 (m-6H, 3CH~2~-aliphatic), 1.90 (s, 3H, CH~3~-18), 3.33 (s, 3H, OCH~3~), 6.90-7.50(m, 9H, aromatic), 9.90 (s, 1H, NH exchangeable). ^13^CNMR (DMSO, ppm): δ =34.80 (C-1), 54.60 (C-3), 36.70 (C-4), 38.80 (C-5), 25.20 (C-6), 27.90 (C-7), 35.70 (C-8), 43.20 (C-9), 46.50 (C-10), 22.70 (C-11), 35.72 (C-12), 46.40 (C-13), 46.20 (C-14), 27.30 (C-15), 29.80 (C-16), 47.90 (C-17), 20.40 (C-18), 21.10 (C-19), 96.10, 145.50, 146.80, 158.90 (C-pyrimidine), 131.60, 139.90 (C=C), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH2-aliphatic), 35.80, 28.10 (CH-aliphatic), 56.10 (C-OCH~3~), 114.20, 127.40, 159.90 (C-aromatic). MS (EI): m/z(%): 673 (M^+^+1, 20), 567 (48), 477 (28), 108 (7). Calc for C~45~H~60~N~4~O (672.480): C, 80.00; H, 9.26; N, 8.30%, found: C, 80.2; H, 9.52; N, 8.42%.

General procedure for compounds 4 and 5 {#sec2-4}
---------------------------------------

To a mixture of compound 1 (0.57 g, 1 mmol) and hydrazine hydrate 98% (0.05 g, 1 mmol) or phenyl hydrazine (0.10 g, 1mmol) in absolute ethanol (30 ml), 1ml of triethylamine was added. The reaction mixture was heated under reflux about 3-5 hours, the reaction mixture was monitored by TLC, after complete disappearance of the reactant, the solvent was evaporated under reduced pressure and the residue oil was solidified by boiling in the petroleum ether. The result product was purified with appropriate solvent.

11-(4-Methoxyphenyl)-12a, 14a-dimethyl-1-octyl-1, 2, 3, 3a, 3b, 4, 5, 5a, 6, 6a, 8, 9, 12, 12a, 12b, 13, 14, 14a-octadecahydrocyclopenta\[5,6\]naphtho\[1,2-g\]pyrazolo\[3,4-b\]quinolin-10(10aH)-imine (4).

White yellowish crystals from absolute ethanol, yield 0.23 g (40%); mp 93- 95 °C; IR (KBr, cm^-1^): υ 3409 (NH), 2932, 2867 (CH-aliphatic),1567 (C=C). 1H NMR (DMSO-d~6~, ppm): δ= 0.76 (s, 3H, CH~3~-19), 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 1.16 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.70 (s, 3H, OCH~3~), 6.45-7.18 (m, 6H, aromatic and NH). ^13^CNMR (DMSO, ppm): δ =34.80 (C-1), 58.10 (C-3), 35.70 (C-4), 38.80 (C-5), 25.20 (C-6), 27.90 (C-7), 35.70 (C-8), 43.20(C-9), 46.50 (C-10), 22.70 (C-11), 35.72 (C-12), 46.40 (C-13), 46.20 (C-14), 27.30 (C-15), 29.80 (C-16), 47.90 (C-17), 20.80 (C-18), 21.10 (C-19), 127.60, 139.90 (C=C), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 56.10 (C-OCH~3~),114.20, 127.40, 159.90 (C-aromatic). MS (EI): m/z (%):585 (M++1,70), 527 (16), 502 (16), 80 (23), 64 (94). Calc for C~38~H~56~N~4~O (584.880): C, 78.03; H, 9.65; N, 9.58, found: C, 78.18; H, 9.37; N, 9.49 %.

11-(4-Methoxyphenyl)-12a,14a-dimethyl-1-octyl-9-phenyl1, 2, 3, 3a, 3b, 4, 5, 5a, 6, 6a, 8, 9, 12, 12a, -12b, 13, -14, 14aoctadecahydrocyclopenta\[5,6\]naphtho\[1,2-g\]pyrazolo\[3,4-b\]quinolin-10(10aH)-imine (5).

Pale brown crystals from absolute ethanol, yield 0.43 g (66%); mp 85-87 °C; IR (KBr, cm^-1^): υ 3424 (NH), 2936, 2864 (CH-aliphatic), 1565 (C=C).^1^HNMR (DMSO-d~6~, ppm): δ= 0.78 (s, 3H, CH~3~-19), 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 1.15 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.73 (s, 3H, OCH~3~), 6.99-7.80 (m, 11H aromatic hydrogen and 2NH). ^13^CNMR (DMSO, ppm): δ =34.80 (C-1), 58.70 (C-3), 35.70 (C-4), 38.80 (C-5), 25.20 (C-6), 27.90 (C-7), 35.70 (C-8), 43.20 (C-9), 46.50 (C-10), 22.70 (C-11), 35.72 (C-12), 46.40 (C-13), 46.20 (C-14), 27.30 (C-15), 29.80 (C-16), 47.90 (C-17), 20.80 (C-18), 21.10 (C-19), 127.60, 139.90 (C=C), 19.40, 23.20, 23.20 (CH~3~ aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 56.10 (C-OCH~3~), 114.20, 127.40, 159.90 (C-aromatic). MS (EI): m/z (%):661 (M^+^+1, 10), 647 (7), 567 (20), 80 (23), 64 (94). Calc for C~44~H~60~N~4~O (660.48): C, 79.95; H, 9.15; N, 8.48, found: C, 79.87; H, 9.30; N,8.32%.

General procedure for compounds 6 and 7 {#sec2-5}
---------------------------------------

To a suspension of compound 1 (0.57 g, 1mmol) in freshly prepared sodium ethoxide, equimolar amount of urea (0.06 g, 1 mmol) or thiourea (0.07 g, 1 mmol) in absolute ethanol was added dropwise with stirring. After that the reaction mixture was heated under reflux for 3-5 hr until the starting materials had disappeared as indicated by TLC. The solvent was evaporated under vacuum and the remaining solids were treated with ethanol (70%) and the result powder was crystallized from proper solvent.

11-Imino-12-(4-methoxyphenyl)-13a, 15a-dimethyl-1-octyl-3, 3a, 3b, 4, 5, 5a, 6, 6a, 8, 10, 11, 11a, 13, -13a, 13b, 14, 15, 15a-octadecahydro-1H-cyclopenta\[5,6\]naphtho\[1,2-g\]pyrimido\[4,5-b\]quinoline-9(2H)-thione (6).

White crystals from absolute ethanol, yield 0.34 g (55%), mp 95-97°C; IR (KBr, cm^-1^): υ 3404 (3NH), 2935, 2867 (CH-aliphatic),1575 (C=C), 1608 (C=N), 1175 (C=S). ^1^HNMR (DMSO-d~6~, ppm): δ= 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 0.95 (s, 3H, CH~3~-19), 1.23 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.73 (s, 3H, OCH~3~), 6.88-7.4 (m, 4H- aromatic-H). 8.65 (s, H, NH, D~2~O-exchangeable), 9.51 (s, 2H, 2NH, D~2~O-exchangeable), ^13^CNMR (DMSO-d~6~-ppm): δ=34.10 (C-1), 53.10 (C-3), 33.20 (C-4), 37.20 (C-5), 25.30 (C-6), 25.80 (C-7), 34.70 (C-8), 42.90 (C-9), 44.10 (C-10), 20.80 (C-11), 31.40 (C-12), 43.80 (C-13), 46.00 (C-14), 21.20 (C-15), 23.70 (C-16), 42.90 (C-17), 20.30 (C-18), 20.80 (C-19), 44.00, 156.40, 178.20 (C-pyrimidine), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 164.60 (C=N), 56.00 (C-OCH~3~), 186.00 (C=S), 114.00, 127.20, 161.20 (C-aromatic). MS (EI): m/z (%): 628 (M^+^, 60), 616 (17), 598 (14), 528 (15), 80 (29), 64 (97). Calc for C~39~H~56~N~4~OS (628.953): C, 74.48; H, 8.97; N, 8.91; S, 5.10, found: C,74.34; H, 8.85; N, 8.72; S, 5.03%.

11-Imino-12-(4-methoxyphenyl)-13a, 15a-dimethyl-1-octyl-3, 3a, 3b, 4, 5, 5a, 6, 6a, 8, 10, 11, 11a, -13, 13a, 13b, 14, 15, 15a-octadecahydro-1H-cyclopenta\[5,6\]naphtho \[1,2-g\] pyrimido \[4,5-b\] quinolin-9 (2H)-one (7).

White crystals from absolute ethanol, yield 0.30g (50%), mp 95-96 °C; IR (KBr, cm^-1^): υ 3387 (3NH), 2932, 2866 (CH-aliphatic), 1672 (C=O), 1574 (C=C), 1608 (C=N). 1H NMR (DMSO-d~6~, ppm): δ= 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.92 (s, 3H, CH~3~-19), 0.93 (d, 3H, 21-CH~3~), 1.23 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.73 (s, 3H, OCH~3~), 6.44--7.40 (m, 7H-aromatic-H and 3NH). ^13^CNMR (DMSO-d~6~-ppm): δ=34.40 (C-1), 58.20 (C-3), 35.10 (C-2), 33.20 (C-4), 37.20 (C-5), 25.20 (C-6), 25.80 (C-7), 29.60 (C-8), 42.90 (C-9), 35.40 (C-10), 20.80 (C-11), 31.40 (C-12), 42.90 (C-13), 46.20 (C-14),21.20 (C-15), 23.70 (C-16), 43.80 (C-17), 20.00 (C-18), 20.40 (C-19), 44.30, 154.40, 156.40 (C-pyrimidine), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 56.20 (C-OCH~3~), 162.00 (C=O), 114.00, 127.20, 161.20 (C-aromatic). MS (EI): m/z (%): 612 (M^+^, 70), 502 (26), 383 (7), 255 (45). Calc for C~39~H~56~N~4~O~2~ (612.888): C, 76.43; H, 9.21; N, 9.14, found: C, 76.70; H, 9.35; N, 9.32%.

General procedure for compounds 8 and 9 {#sec2-6}
---------------------------------------

To a solution of compound 1 (0.57 g, 1mmol) in 15 ml potassium ethoxide (10%), carbon disulfide (1 mmol, 0.07 g) was added for the synthesis of compound 8 and excess (0.21 g) for the synthesis of compound 9 was added. the reaction mixture was heated under reflux for 4 hours until all starting materials had disappeared as indicated by TLC. The solvent was evaporated under vacuum and the remaining oil was treated with ice/water mixture and neutralized with dilute HCL. The obtained solid product was collected by filtration, dried, and crystallized from absolute ethanol.

12-(4-Methoxyphenyl)-13a, 15a-dimethyl-1-octyl-9-thioxo-3, 3a, 3b, 4, 5, 5a, 6, 6a, 8, 9, 10, -11a, 13, 13a, -13b, 14, 15, 15a-octadecahydro-1H-cyclopenta \[5,6\] naphtho \[1,2-g\] pyrimido \[4,5-b\] quinolin-11 (2H)-one (8).

Yellow crystals, yield 0.50 g (80%), mp 93-95 °C; IR (KBr, cm^-1^): υ 3423 (NH), 2932, 2866 (CH-aliphatic), 1611 (C=O), 1567 (C=C), 1175 (C=S). ^1^HNMR (DMSO-d~6~, ppm): δ= 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 0.96 (s, 3H, CH~3~-19), 1.29 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.79 (m, 3H, OCH~3~), 7.05-7.18 (m, 6H, aromatic hydrogen and 2NH). ^13^CNMR (DMSO-d~6~-ppm): δ=34.00 (C-1), 34.40 (C-2), 35.20 (C-3), 33.20 (C-4), 37.20 (C-5), 25.30 (C-6), 25.80 (C-7), 29.60 (C-8), 42.90 (C-9), 35.40 (C-10), 20.80 (C-11), 31.40 (C-12), 42.90 (C-13), 46.00 (C-14), 21.20 (C-15), 23.20 (C-16), 43.80 (C-17), 20.20 (C-18), 20.50 (C-19), 48.80, 156.40, 172.70, 175.20 (C-pyrimidine), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic), 183.00 (C=S), 167.60 (C=O), 56.10 (C-OCH~3~), 127.00, 114.00, 161.00 (C-aromatic). MS (EI): m/z (%): 630 (M^+^+1,70), 615 (17), 585 (12), 542 (4), 80 (26), 64 (97). Calc for C~39~H~55~N~3~O~2~S (629.401): C, 74.10; H, 8.67; N, 6.82; S, 5.21, found: C, 74.28; H, 8.50; N, 6.72; S, 5.32 %.

12-(4-Methoxyphenyl)-13a, 15a-dimethyl-1-octyl-3, 3a, 3b, 4, 5, 5a, 6, 6a, 10, 11a, 13, 13a, 13b, 14, 15, 15a-hexadecahydro-1H-cyclopenta \[5,6\] naphtho \[1,2-g\] pyrimido \[4,5-b\] quinoline-9,11 (2H,8H)-dithione (9).

Dark yellow crystals from absolute ethanol, yield 0.45 g (70%), mp 95 °C; IR (KBr, cm^-1^): υ 3402 (2NH), 2934, 2867 (CH-aliphatic),1574 (C=C), 1608 (C=N), 1248, 1175 (2C=S). ^1^HNMR (DMSO-d~6~, ppm): δ= 0.85 (d, 6H, 26-CH~3~, 27-CH~3~), 0.93 (d, 3H, 21-CH~3~), 0.96 (s, 3H, CH~3~-19), 1.29 (s, 3H, CH~3~-18), 1.25-1.33 (m-6H, 3CH~2~-aliphatic), 3.74 (S, 3H, OCH~3~), 6.99-7.42 (m, 6H, aromatic hydrogen and 2H, NH). ^13^CNMR (DMSO- d~6~, ppm): δ=35.0 (C-1), 35.10 (C-3), 33.20 (C-4), 37.20 (C-5), 25.30 (C-6), 25.80 (C-7), 29.60 (C-8), 42.90 (C-9), 35.40 (C-10), 20.80 (C-11), 31.40 (C-12), 42.90 (C-13), 46.00 (C-14), 21.20 (C-15), 23.20 (C-16), 43.80 (C-17), 20.20 (C-18), 20.50 (C-19), 75.50, 130.40, 186.30, 194.00 (C-pyrimidine), 19.40, 23.20, 23.20 (CH~3~-aliphatic), 36.10, 24.60, 39.30 (CH~2~-aliphatic), 35.80, 28.10 (CH-aliphatic),186.30 (C=S), 56.10 (C-OCH~3~),114.00, 127.20 (C-aromatic). MS (EI): m/z (%):645(M^+^-1, 43), 585 (14), 542 (20), 276 (28), 80 (26), 64 (97). Calc for C~39~H~55~N~3~OS~2~ (646.004): C, 72.22; H, 8.45; N, 6.65; S, 10.15, found: C, 72.50; H, 8.39; N,6.51; S, 10.32 %.

Preparation of PEG-based Nanoparticles {#sec2-7}
--------------------------------------

PEG-based nanoparticles, namely PEG-based cholestane heterocyclic derivatives nano emulsions (N1-N9), were synthesized using precipitation method (Vaculikova et al., 2012). Briefly, 2 ml Tween 80, 0.1 g sodium dodecyl sulfate (SDS), 0.3 g polyethylene glycol (PEG-macrogol 6,000), 0.5g sodium carboxy methyl cellulose (SCMC) and 1 g sodium carboxy methyl dextran (SCMD) were used as excipients. The excipients were dissolved in 10ml deionized water. The aqueous solutions of excipients were stirred for 10 min at 35 °C and 600 rpm. 0.04 g of each one of cholestane heterocyclic derivatives was dissolved in 2ml absolute ethanol; i.e., 2% solutions were prepared. The prepared solutions of the cholestane derivatives in ethanol were slowly dropped (2 ml) to the aqueous solutions (10 ml) of excipients. Then the system was stirred for 30 min and sonicated in ultrasonic water bath for 40 min as described in (Vaculikova et al., 2012).

Characterization of PEG-based Nanoparticles {#sec2-8}
-------------------------------------------

The particle size distribution and zeta potential of the synthesized nanosized cholestane heterocyclic derivatives (N1-N9) were measured by Malvern Zetasizer system (Malvern Instruments, Westborough, Massachusetts). In Zetasizer, 1ml of the nanoparticles solution was filled in the disposable transparent sizing clear cuvette and sample was analyzed at 25 °C. The morphology and particle size of synthesized nanosized (N1-N9) were evaluated by Transmission Electron Microscope (TEM).

Dialysis of PEG-based Nanoparticles and entrapment efficiency measurement {#sec2-9}
-------------------------------------------------------------------------

### Sample preparation for injection onto HPLC {#sec3-1}

Each PEG-loaded NP (0.1 ml) was diluted to 1ml and further diluted twice (1:10) with methanol. 50 μl was injected and drug content was determined by the reported High performance liquid chromatography (HPLC) method (Dueland et al., 1982).

HPLC condition {#sec2-10}
--------------

HPLC system Agilent1100 series with Quat pump a SPD-20A UV Visible variable wavelength detector set at 254 with deuterium lamp, and a 250 x 4.6 mm, 5 μ, C-18 reverse phase analytical column was used to determine total drug content and entrapment efficiency of the formulations. The mobile phase consisted of acetonitrile/ultrapure water 65/35 (v/v) was eluted at a flow rate 1 ml/min. Serial dilutions of standard were injected onto HPLC and their peak areas were determined. A linear standard curve was constructed by plotting peak areas versus the corresponding concentrations, the concentrations in samples were obtained from the standard curve.

The drug entrapment efficiency (EE) was calculated from the ratio of amount of drug obtained by HPLC (drug content in the synthesized PEG-based nanoparticles) to the total added starting amount of drug (0.04 g). Entrapment efficiency of drugs was determined by filtering a known amount of drug-loaded nanoparticles through a 10K MWCO filter dialysis membrane (Amicon, Millipore, Schwalbach, D) to separate the free drug.

In-vitro Cytotoxic Assay {#sec2-11}
------------------------

### Cell propagation and maintenance {#sec3-2}

Hepatocellular carcinoma cells HepG2, breast cancer cells MCF-7 and colon cancer cells HCT116 were purchased from American Type Culture Collection (ATCC), and maintained under the proper conditions. The cells were cultured in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St Louis, Missouri, USA) supplemented with 100 IU/ml penicillin G sodium, 100 lU/ml streptomycin sulfate, 1% l-glutamine, and 10% fetal bovine serum at 37 °C in a humidified incubator with 5% CO~2~. The cells were harvested after trypsinization (0.025% trypsin and 0.02% Ethylenediaminetetraaceticacid (EDTA) and washed twice with, Dulbecco's phosphate-buffered saline (DPBS) (Bio-Whittaker, Lonza, Verviers, Belgium). When the cell density reached \~80%, cells were splitted for further culture. The experiments were conducted when the cells were in the logarithmic growth phase.

### Cytotoxicity Assay {#sec3-3}

Cell viability was measured using a neutral red uptake assay (Repetto et al., 2008). The neutral red uptake assay provides a quantitative estimation of the number of viable cells in a culture. It is based on the ability of viable cells to incorporate and bind the supravital dye neutral red in the lysosomes. The cells were incubated with various concentrations of the tested compounds (6.25, 12.5, 25, 50 µmol/l) for 48 h at a cell density of 10^4^ cells/well of a 96-well plate. A neutral red working solution (0.4 µg/ml) (Sigma-Aldrich) was incubated overnight at 37°C in the same manner as the treated cells. In each well of the incubated cells, culture media were removed and neutral red medium (100 µl) was added, and then incubated for 2 h to allow for vital dye incorporation into living cells. The neutral red media were removed and rinsed rapidly with Dulbecco's PBS buffer (150 µl). Dye was extracted from the cells by adding extraction buffer \[150 µl, 1% acetic acid: 50% ethanol (96%): 49% deionized H~2~O\], followed by rapid agitation for at least 10 min on a micrometer plate shaker. The extract neutral red color intensity was measured at 530 and 645 nm as excitation and emission wavelengths in a micro-titer plate reader spectrophotometer (Sorin, Biomedica S.p.A., Milan, Italy). Using the relation between log concentrations used and the neutral red intensity value, the IC~50~ of the tested compounds were calculated. For the untreated cells (negative control), medium was added instead of the test compounds. A positive control Adrinamycin (doxorubicin) (Mr = 579.9) for HepG2, Cisplatin (Mr = 300.05) for HCT116, and Tamoxifen (Mr = 371.51) for MCF-7 were used as a cytotoxic natural agents yielding 100% inhibition. Dimethyl sulfoxide (DMSO) was the vehicle used for dissolution of the tested compounds and its final concentration on the cells was less than 0.2%. All tests and analyses were carried out in triplicate and the results were averaged.

### Molecular Docking Study {#sec3-4}

Molecular modeling study was initiated in order to interpret the biological results and to determine further information about the binding orientations of the tested compounds and optimize a reliable model for predicting novel effective anti-tumor hits. Docking study was carried out for the target compounds into protein tyrosine kinase (PTK) using Discovery Studio 2.5 software (Accelrys Inc., San Diego, CA, USA). The docking study of the newly hybrid synthesized compounds was carried out, which were docked within the protein tyrosine kinase (PDB code: 1t46) (Shrestha et al., 2008). Interactive docking using C-DOCKER protocol was carried out for all the conformers of each compound of the tested set (1-9) to the selected active site, after energy minimization using prepared ligand protocol. Protein structure was prepared and the invalid or missing residues were added (Accelrys Inc., 2003). Re-docking lead compound with the same binding site showed docking energy = - 48 kcal/mol with small RMSD (0.909A) deviation in comparison to its crystal structure ([Figure 1](#F1){ref-type="fig"}). The small RMSD values proved the validity of the used docking processes (Johnsona et al., 2002). Each docked compound was assigned a score according to its binding mode onto the binding site (Vulpetti et al., 2005). In the study, the lead compound (STI-571) \[4-\[(4-methylpiperazin-1-yl)methyl\]-N-\[4-methyl-3-\[(4-pyridin-3-ylpyrimidin-2-yl)amino\]-phenyl\]-benzamide, commonly known as Imatinib or Gleevec was docked into its C-kit receptor PTK (PDB code: 1t46). It was found that the steroids derivatives were favorably fitted into the binding pocket of PTK which was comparable with the native ligand. Therefore, the STI-571 was selected as a reference ligand for the comparative study of binding action of the synthesized compounds in this study.

![Validation of Accuracy and Performance of the Docking Algorithm (C-DOCKER). The docked STI ligand nearly superimposed on the native STI ligand exhibiting same number of hydrogen bonds with same amino acids involved by the native one](APJCP-18-1937-g001){#F1}

Results {#sec1-3}
=======

Chemistry {#sec2-12}
---------

One pot multicomponant reactions were attempted as a straight forward method for the synthesis of heterocyclic steroids. A mixture of 5α-cholestane-3-one, p-methoxybenzaldahyde and malononitrile was heated under reflux for 5 hours in absolute ethanol containing a catalytic amount of piperdine to afford the corresponding aminocholestanopyran derivative 2 ([scheme 1](#F2){ref-type="fig"}). The formation of pyran derivative 2 can be explained by the possible mechanism represented in [scheme 2](#F3){ref-type="fig"}. The reaction occur via initial formation of the intermediate acrylonitrile A followed by its nucleophilic attack of the anion of cholestanone to produce the intermediate B. The final product D was formed via the initial cyclization and subsequent tautomerization of the cyclic intermediate C. To survey the scope of this reaction for the synthesis of pyran and pyridine derivatives, different catalysts were used, thus the multicomponant reactions of cholestanone with malononitrile and p-methoxybenzaldahyde in absolute ethanol containing catalytic amount of ammonium acetate gave the aminocholestanopyridine derivative 1 ([scheme 1](#F2){ref-type="fig"}). All microanalytical and spectroscopic data were in accordance with the suggested compounds1 and 2 (c.f. Materials and Methods).

![](APJCP-18-1937-g002){#F2}

![](APJCP-18-1937-g003){#F3}

The aminocholestanopyridine adduct 1 was allowed to react with aniline in glacial acetic acid to afford the corresponding cholestanopyridopyrimidine derivative 3 ([scheme 3](#F4){ref-type="fig"}). On the other hand the reaction of compound 1with hydrazine hydrate or phenyl hydrazine in absolute ethanol containing a catalytic amount of triethylamine afforded the corresponding cholestanopyridopyrazole derivatives 4 or 5 respectively ([scheme 3](#F4){ref-type="fig"}). For more utility of the pervious method to synthesize different active heterocyclic steroids, urea and thiourea were used. The reaction of aminocholestanopyridine derivative 1 with equimolar amount of urea or thiourea in freshly prepared sodium ethoxide afforded the corresponding cholestanopyridopyrimidine derivatives 6 or 7 respectively ([scheme 4](#F5){ref-type="fig"}).

![](APJCP-18-1937-g004){#F4}

![](APJCP-18-1937-g005){#F5}

Aminocholestanopyridine derivative 1 was allowed to react with equimolar amount of carbon disulfide in alcoholic potassium hydroxide solution (10%) to form the corresponding cholestanopyridopyrimidine-thione derivative 8 ([scheme 5](#F6){ref-type="fig"}). Meanwhile, carrying out the pervious reaction in the presence of excess of carbon disulfide afforded the cholestanopyridopyrimidine-dithione derivative 9 ([scheme 5](#F6){ref-type="fig"}). Analytical and spectral data of all products were consistent with their respective structures.(c.f. Materials and Methods).

![](APJCP-18-1937-g006){#F6}

Characterization of PEG Nanoparticles {#sec2-13}
-------------------------------------

Particle size distribution and zeta potential of the synthesized drug nanoparticles are shown in Figures [2](#F7){ref-type="fig"} and [3](#F8){ref-type="fig"} and the data-values are summarized in [Table 1](#T1){ref-type="table"}. The formulation code of compound 1-9 are N1-N9 respectively, it appears that most of the particles having comparable sizes and less than 100 nm. The relatively changes in the sizes might be due to the nature of structure and composition of each drug derivative. The average particle size are 22.25, 25.9, 7.63, 2.85, 20.5, 60.9, 227.9, 15.79, 18.37 nm for N1, N2, N3, N4, N5, N6, N7, N8, N9, respectively. The results of zeta potential indicate the stability of the synthesized drug nanoparticles with the surface negative charges ranging between -19 to -36. The values and type of charges on the particle are depending on the composition and structure of the particle as well as the medium in which the particles are suspended. The obtained values of zeta potential are -19.3, -27.4, -35.2, -35.8, -32.1, -30.5, -34.7, -26.2 and -28.8 mv for N1, N2, N3, N4, N5, N6, N7, N8 and N9, respectively.

![Zeta Potential of Synthesized PEG-Based Nanoparticles](APJCP-18-1937-g007){#F7}

![Particle Size Distribution of Synthesized PEG-Based Nanoparticles](APJCP-18-1937-g008){#F8}

[Figure 4](#F9){ref-type="fig"} depicts TEM image of the synthesized core-shell PEG-drug nanoparticles. Spherical drug nano particle coated with thin layer of PEG is appeared in the photograph. The core drug particle might be composed of several agglomerated nanoparticles.

![TEM Image of Synthesized Core-Shell PEG-Drug Nanoparticle](APJCP-18-1937-g009){#F9}

###### 

Particle Size, Zeta Potential and Determined Concentration of the Prepared PEG-Based Nanoparticles

  Formulation code   Size (nm)   Zeta potential (mV)   HPLC/Conc. (µg/ml)
  ------------------ ----------- --------------------- --------------------
  N1                 22.25       -19.3                 81.7
  N2                 25.94       -27.4                 760.0
  N3                 7.63        -35.2                 25.3
  N4                 2.85        -35.8                 633.0
  N5                 20.5        -32.1                 156.8
  N6                 60.88       -30.5                 348.0
  N7                 227.90      -34.7                 348.0
  N8                 15.79       -26.2                 0.0
  N9                 18.37       -28.8                 867.0

The results of measured entrapped drug concentration by HPLC inside the synthesized core-shell nanoparticles after dialysis are illustrated in [Table 1](#T1){ref-type="table"}. The measured concentration values are 81.7, 760, 25.3, 633, 156.8, 348, 348, 0 and 867 µg/ml for N1, N2, N3, N4, N5, N6, N7, N8 and N9, respectively. Big differences in the values of entrapped concentrations are detected. This might be depending on the structure and composition of each derivative.

Cytotoxic Activity Assay {#sec2-14}
------------------------

The newly synthesized compounds were investigated individually in their free and PEG based nano size form as anticancer agents against the three human cell lines namely, HepG2, MCF-7 and HCT116 at concentrations of (6.25, 12.5, 25, 50 µmol/l.). The inhibition of proliferation of these cell line was determined using a neutral red assay, which is based on the ability of viable cells to incorporate and bind the supravital dye neutral red in the lysosomes.

The free tested compounds, in normal size, did not show significant effect on cell proliferation; however, their encapsulated nano-form affected significantly on cell growth inhibition as compared to the control cells. From the data obtained ([Table 2](#T2){ref-type="table"}, [Figure 5](#F10){ref-type="fig"}), the tested compounds showed significant cell growth inhibition against HepG2 cells, the most active compounds were in the descending order of 6\>3\>1\>7\>5\>2\>4\>9. Doxorubicin was used as a reference drug (IC~50~, 2.63 µmol/l). Regarding MCF-7 cells where tamoxifen was used as a reference drug (IC~50~, 3.09 µmol/l), as shown in [Table 2](#T2){ref-type="table"} and [Figure 6](#F11){ref-type="fig"}, the most active compounds against the MCF-7 were in the descending order of 1\>3\>4\>9\>7\>6\>5\>2. Concerning HCT116 cells, where cisplatin was used as a reference drug (IC~50~ 4.67 µmol/l), the most active compounds against the HCT116 cancer cell line were in the descending order of 6\>3\>9\>4\<7\>1\>5\>2 ([Table 2](#T2){ref-type="table"}, [Figure 7](#F12){ref-type="fig"}).

###### 

*In-Vitro* Cytotoxic Activity of the Newly Synthesized PEG Based Nanoparticles Compounds on the Hepg2, MCF-7, HCT116 Cancer Cell Line

  IC~50~ (mmol/l)                                           
  ----------------- -------------------- ------------------ ------------------
   N1               8.51                 2.45               26.3
   N2               40.73                41.6               48.9
   N3               8.31                 2.45               3.21
   N4               42.6                 2.88               10.11
   N5               25.5                 31.6               37.1
   N6               2.44                 3.46               2.59
   N7               12.02                3.09               17.3
   N9               50                   3.08               10.09
  Reference drug    Doxorubicin = 2.63   Tamoxifen = 3.09   Cisplatin = 4.67

![Effect of PEG Based Nanoparticles Compounds (1-7) and Doxorubicin (Dox) on Hepg2 Cancer Cell Line Growth](APJCP-18-1937-g010){#F10}

![Effect of PEG Based Nano Particles Compounds (1-9) and Tamoxifen (TAM) On MCF-7 Cancer Cell Line Growth](APJCP-18-1937-g011){#F11}

![Effect of PEG Based Nano Particles Compounds (1-9) and Cisplatin (Cis) on HCT116 Cancer Cell Line](APJCP-18-1937-g012){#F12}

The existence of \[1,2-g\] pyrimido \[4,5-b\] quinoline-9(2H)-thione at position 5 and 6 of naphthalene ring at compound 6 showed growth inhibition with IC~50~ values of 2.44 µmol/l, 3.46 µmol/l and 2.59 µmol/l against the three tested cell lines HepG2, MCF-7 and HCT116 respectively. Whereas, the existence of pyridine ring incorporated to compound 1 showed IC~50~ value of 2.45 µmol/l against MCF-7 cells.

Discussion {#sec1-4}
==========

Molecular Docking Study {#sec2-15}
-----------------------

The synthesized hybrid compounds are composed of two parts, due to the existence of bulky lipophilic cholestane moiety, the main interaction enrolled in the docking simulation was van der Waals forces, most of the compounds displayed only one hydrogen bonding with the PTK receptor [Table 3](#T3){ref-type="table"}. Almost all compounds showed similar binding affinities when compared with the native bound STI-571 ligand. The affinity of these hybrid compounds could be related to the high lipophilicity of the steroid moiety of the compound, due to which better van der Waals interaction was proposed betweenthe receptor and ligand. Compound 6 in its PEG based nano size revealed the best cytotoxic effect against HepG2 and HCT116 cell lines with IC~50~ 2.44 µmol/l and 2.59 µmol/l, respectively. Besides it showed a considerable low IC~50~ value against MCF-7 (3.46 µmol/l). Regarding the docking study it exhibited two hydrogen bonds with Cys788 and Ile789 showed C-DOCKER Interaction energy= 45.5 kcal/mol) with RMSD= 0.32 [Figure 8](#F13){ref-type="fig"}. Consequently, the docking results were confirmed by the laboratory cytotoxic studies in [Table 2](#T2){ref-type="table"}.

###### 

The Best Docking Score and Binding Energy of Compounds Docked Into PTK, and the Distances and Angles of Hydrogen Bonds between Compounds and Amino Acids Involved in PTK

  Compound   C-DOCKERInteraction energy (kcal/mol)   Binding energy (kcal/mol)   Hydrogen bonds between compounds and amino acid   RMSD (A°)          
  ---------- --------------------------------------- --------------------------- ------------------------------------------------- ----------- ------ ------
  1          47.3                                    18                          Ar-OCH~3~                                         Lue813      1.92   0.66
  2          41.2                                    20                          Ar-OCH~3~                                         Lue813      2.12   1.02
  3          44.7                                    16                          Ar-OCH~3~                                         Lue813      1.95   0.75
  NH         His790                                  2.01                                                                                             
  4          44.5                                    21                          Ar-OCH~3~                                         Phe811      2.16   0.88
  5          \-                                      \-                                                                                        \-     \--
  6          45.5                                    19                          NH                                                Cys788      2.43   0.32
  N          Ile789                                                                                                                                   
  7          46.3                                    21                          N                                                 Cys788      2.01   0.75
  8          40.2                                    24                          \-                                                \-          1.89   1.25
  9          45.1                                    17                          Pyrazole NH                                       Cys788      2.25   1.02

![Docking Pose of the Target Compounds 6 to rhe Active Site of PTK which Exhibited Two Hydrogen Bond Shown as a Green Line with Amino Acid Cys 788 And Ile789.](APJCP-18-1937-g013){#F13}

In conclusion, this study introduced a facile synthesis of newly promising anticancer hybrid steroid derivatives via MCRs, and emphasized also the importance of converting heterocyclic steroids into PEG-based nanoparticles to form new effective anticancer agents. Compound 6 in its PEG based nano size revealed the best cytotoxic effect against HepG2 and HCT116 cell lines. Besides it showed a considerable low IC~50~ value against MCF-7. Finally, we recommend these heterocyclic steroidal nanoparticles as target for extension studies before going through phase 1 of clinical trials.
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